[
    {
        "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
        "text": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers."
    },
    {
        "headline": "Moderna, Inc. (MRNA): Among the Best Growth Stocks to Buy and Hold for the Long Term",
        "text": "We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]"
    },
    {
        "headline": "Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "Trump expected to sign order to slash US drug prices",
        "text": "President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Why Moderna Merged Its Tech and HR Departments",
        "text": "The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech."
    },
    {
        "headline": "Moderna, Inc. (MRNA): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential",
        "text": "We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against billionaire David E. Shaw’s other small-cap stock picks with huge upside potential. David E. Shaw is one billionaire investor whose […]"
    },
    {
        "headline": "Moderna (NasdaqGS:MRNA) Expands AI-Ready Collaboration With Benchling For R&D Transformation",
        "text": "Moderna (NasdaqGS:MRNA) recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1..."
    },
    {
        "headline": "Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025",
        "text": "CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ..."
    },
    {
        "headline": "Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks",
        "text": "Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season."
    },
    {
        "headline": "Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)",
        "text": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT)."
    },
    {
        "headline": "Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development",
        "text": "Flagship Pioneering, the bioplatform innovation company, the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH) and the National University Health System (NUHS) today announced a research and development collaboration to advance outcomes in human health and sustainability. Flagship, NUS Medicine, NUH and NUHS outlined the goals of their collaboration via a Memorandum of Understanding (MOU) signed this week."
    },
    {
        "headline": "Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator",
        "text": "Dr. Vinay Prasad succeeds Dr. Peter Marks, who left the role of leader of the FDA’s Center for Biologics Evaluation and Research in March."
    },
    {
        "headline": "Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1",
        "text": "Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales."
    },
    {
        "headline": "3 Cash-Heavy Stocks in the Doghouse",
        "text": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers."
    },
    {
        "headline": "Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss",
        "text": "Moderna (NasdaqGS:MRNA) recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was relatively flat over the last month. This performance aligns with broader market trends, which saw significant gains due to strong job reports and positive sentiment from potential U.S.-China trade talks. While Moderna's financial results may have added weight to broader market optimism, the stock's minimal..."
    },
    {
        "headline": "Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say",
        "text": "The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals."
    },
    {
        "headline": "Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ...",
        "text": "Despite a significant revenue drop, Moderna Inc (MRNA) focuses on financial discipline and pipeline growth to drive future success."
    },
    {
        "headline": "Q1 2025 Moderna Inc Earnings Call",
        "text": "Q1 2025 Moderna Inc Earnings Call"
    },
    {
        "headline": "Moderna Cuts Costs as COVID Sales Slump",
        "text": "Trims 2026 operating expenses by up to $500M after Q1 revenue plunges 35% to $108M"
    },
    {
        "headline": "Moderna combination flu, COVID shot delayed amid FDA scrutiny",
        "text": "Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines."
    },
    {
        "headline": "Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses",
        "text": "As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers."
    },
    {
        "headline": "Moderna, Inc. (MRNA): Among the Best Growth Stocks to Buy and Hold for the Long Term",
        "text": "We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]"
    },
    {
        "headline": "Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "Trump expected to sign order to slash US drug prices",
        "text": "President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief&nbsp;here."
    },
    {
        "headline": "Why Moderna Merged Its Tech and HR Departments",
        "text": "The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech."
    },
    {
        "headline": "Moderna, Inc. (MRNA): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential",
        "text": "We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against billionaire David E. Shaw’s other small-cap stock picks with huge upside potential. David E. Shaw is one billionaire investor whose […]"
    },
    {
        "headline": "Moderna (NasdaqGS:MRNA) Expands AI-Ready Collaboration With Benchling For R&D Transformation",
        "text": "Moderna (NasdaqGS:MRNA) recently expanded its collaboration with Benchling, enhancing its digital infrastructure to foster research innovation. Despite this positive development, Moderna's share price fell 6% over the past month. This decline occurred amid broader market gains, with major U.S. indexes like the Nasdaq and S&P 500 climbing due to optimism around U.S.-UK trade deals and rising cryptocurrency prices. However, Moderna's report of decreased revenues and a significant net loss in Q1..."
    },
    {
        "headline": "Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025",
        "text": "CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ..."
    },
    {
        "headline": "Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks",
        "text": "Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season."
    },
    {
        "headline": "Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)",
        "text": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT)."
    },
    {
        "headline": "Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development",
        "text": "Flagship Pioneering, the bioplatform innovation company, the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH) and the National University Health System (NUHS) today announced a research and development collaboration to advance outcomes in human health and sustainability. Flagship, NUS Medicine, NUH and NUHS outlined the goals of their collaboration via a Memorandum of Understanding (MOU) signed this week."
    },
    {
        "headline": "Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator",
        "text": "Dr. Vinay Prasad succeeds Dr. Peter Marks, who left the role of leader of the FDA’s Center for Biologics Evaluation and Research in March."
    },
    {
        "headline": "Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1",
        "text": "Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales."
    },
    {
        "headline": "3 Cash-Heavy Stocks in the Doghouse",
        "text": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers."
    },
    {
        "headline": "Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss",
        "text": "Moderna (NasdaqGS:MRNA) recently reported a decline in revenue for Q1 2025, but managed to reduce its net loss and improve its loss per share. Despite this, the company's stock price was relatively flat over the last month. This performance aligns with broader market trends, which saw significant gains due to strong job reports and positive sentiment from potential U.S.-China trade talks. While Moderna's financial results may have added weight to broader market optimism, the stock's minimal..."
    },
    {
        "headline": "Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say",
        "text": "The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals."
    },
    {
        "headline": "Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ...",
        "text": "Despite a significant revenue drop, Moderna Inc (MRNA) focuses on financial discipline and pipeline growth to drive future success."
    },
    {
        "headline": "Q1 2025 Moderna Inc Earnings Call",
        "text": "Q1 2025 Moderna Inc Earnings Call"
    },
    {
        "headline": "Moderna Cuts Costs as COVID Sales Slump",
        "text": "Trims 2026 operating expenses by up to $500M after Q1 revenue plunges 35% to $108M"
    },
    {
        "headline": "Moderna combination flu, COVID shot delayed amid FDA scrutiny",
        "text": "Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines."
    },
    {
        "headline": "Moderna First-Quarter Loss Unexpectedly Improves Even as Revenue Drops",
        "text": "Moderna's (MRNA) first-quarter loss unexpectedly improved year on year as a drop in expenses helped"
    },
    {
        "headline": "Moderna Shares Drop As Political Picture Worsens",
        "text": "Moderna laid out plans Thursday to slash future costs in an effort to stop bleeding cash, but a worsening political environment for vaccine companies is making its plan a tough sell. Moderna stuck by its prior guidance and reported a quarterly loss of $2.52 a share; the consensus estimate was a per-share loss of $3.12. Revenue was $108 million, in line with the $106 million consensus estimate."
    },
    {
        "headline": "Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts",
        "text": "MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027."
    },
    {
        "headline": "Wayfair beats, Estee Lauder outlook, Moderna: Trending Tickers",
        "text": "Wayfair (W) stock gains after reporting a surprise earnings beat, with the company saying its business model should minimize tariff impacts. Estee Lauder (EL) warns of a slowdown in sales in 2025 but expects a return to growth in 2026, assuming there is more clarity on Trump's tariff policies. Moderna (MRNA) announces plans to cut $1.5 billion after reporting a 35% drop in revenue from the year-ago period. To watch more expert insights and analysis on the latest market action, check out more Wealth here."
    },
    {
        "headline": "Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline",
        "text": "Moderna stock crumbled Thursday after the biotech company missed sales estimates for its two products, Spikevax and mResvia."
    },
    {
        "headline": "Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates",
        "text": "Moderna (MRNA) delivered earnings and revenue surprises of 13.70% and 14.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?"
    },
    {
        "headline": "Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates",
        "text": "Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its GAAP loss of $2.52 per share was 18.6% above analysts’ consensus estimates."
    },
    {
        "headline": "Moderna Posts Loss, Citing Seasonality of Respiratory Business",
        "text": "Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year."
    },
    {
        "headline": "Moderna: Q1 Earnings Snapshot",
        "text": "MRNA) on Thursday reported a loss of $971 million in its first quarter. The Cambridge, Massachusetts-based company said it had a loss of $2.52 per share. The results topped Wall Street expectations."
    },
    {
        "headline": "Moderna says FDA has been constructive, but delays flu/COVID shot",
        "text": "(Reuters) -Moderna on Thursday pushed back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza, but said exchanges with U.S. drug regulators have remained constructive under Health Secretary and vaccine skeptic Robert F. Kennedy Jr. The U.S. vaccine maker reported first-quarter profit and sales that beat Wall Street estimates, as the company's cost-cutting efforts offset some of the waning post-pandemic demand for its COVID shot. The company's shares, which have been battered by declining COVID revenue as well as political concerns spurred by Kennedy's appointment, fell 3.3% to $27.60 in morning trading."
    },
    {
        "headline": "Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates",
        "text": "Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of ..."
    },
    {
        "headline": "Moderna, Inc. (MRNA): Among the Worst Performing Stocks in S&P 500 So Far in 2025",
        "text": "We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for the broad market index since […]"
    },
    {
        "headline": "Moderna (MRNA) Reports Earnings Tomorrow: What To Expect",
        "text": "Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know."
    },
    {
        "headline": "Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for",
        "text": "Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
    },
    {
        "headline": "Down 36%, Is Moderna a Buy on the Dip?",
        "text": "With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention. This doesn't mean Moderna is inactive; in fact, it's quite the opposite. Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA)."
    }
]